Institutional shares held 32.2 Million
113K calls
106K puts
Total value of holdings $7.3B
$25.6M calls
$24M puts
Market Cap $23.5B
103,700,000 Shares Out.
Institutional ownership 31.05%
# of Institutions 268


Latest Institutional Activity in BGNE

Top Purchases

Q2 2025
Ubs Group Ag Shares Held: 182K ($41.2M)
Q2 2025
Man Group PLC Shares Held: 244K ($55.3M)
Q2 2025
Qube Research & Technologies LTD Shares Held: 108K ($24.4M)
Q2 2025
Baird Financial Group, Inc. Shares Held: 342K ($77.6M)
Q2 2025
Lmr Partners LLP Shares Held: 78.4K ($17.8M)

Top Sells

Q2 2025
Price T Rowe Associates Inc Shares Held: 1.02M ($231M)
Q2 2025
Citadel Advisors LLC Shares Held: 537K ($122M)
Q2 2025
Paradigm Biocapital Advisors LP Shares Held: 348K ($78.8M)
Q2 2025
Capital International Investors Shares Held: 4.89M ($1.11B)
Q2 2025
Morgan Stanley Shares Held: 268K ($60.9M)

About BGNE

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.


Insider Transactions at BGNE

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
10.3M Shares
From 19 Insiders
Grant, award, or other acquisition 1.23M shares
Exercise of conversion of derivative security 9.09M shares
Sell / Disposition
22.7M Shares
From 12 Insiders
Open market or private sale 20.6M shares
Bona fide gift 159K shares
Other acquisition or disposition 29.6K shares
Payment of exercise price or tax liability 1.99M shares

Track Institutional and Insider Activities on BGNE

Follow BeiGene, Ltd. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BGNE shares.

Notify only if

Insider Trading

Get notified when an Bei Gene, Ltd. insider buys or sells BGNE shares.

Notify only if

News

Receive news related to BeiGene, Ltd.

Track Activities on BGNE